Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

AbbVie Inc

ABBV
Current price
149.06 USD -3.4 USD (-2.23%)
Last closed 152.25 USD
Sector Healthcare
Industry Drug Manufacturers-General
Exchange NYSE
Capitalization 269 593 739 264 USD
Yield for 12 month +7.76 %
Week
Month
Year
ABBV
21.11.2021 - 28.11.2021

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; Genentech, Inc.; and California Institute for Biomedical Research (Calibr). The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

Analytics

WallStreet Target Price

169.61 USD

P/E ratio

31.428

Dividend Yield

3.86 %

Current Year

+58 054 000 000 USD

Last Year

+56 197 000 000 USD

Current Quarter

+13 865 000 000 USD

Last Quarter

+12 225 000 000 USD

Current Year

+40 640 000 000 USD

Last Year

+38 751 000 000 USD

Current Quarter

+9 625 000 000 USD

Last Quarter

+8 239 000 000 USD

Key Figures ABBV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 29 195 999 232 USD
Operating Margin TTM 36.5 %
PE Ratio 31.428
Return On Assets TTM 9.18 %
PEG Ratio 1.2788
Return On Equity TTM 63.02 %
Wall Street Target Price 169.61 USD
Revenue TTM 56 022 999 040 USD
Book Value 7.29 USD
Revenue Per Share TTM 31.65 USD
Dividend Share 5.85 USD
Quarterly Revenue Growth YOY -4.9 %
Dividend Yield 3.86 %
Gross Profit TTM 41 527 000 000 USD
Earnings Share 4.86 USD
Diluted Eps TTM 4.86 USD
Most Recent Quarter II 2023
Quarterly Earnings Growth YOY 123.4 %
Profit Margin 15.5 %

Dividend Analytics ABBV

Dividend growth over 5 years

120 %

Continuous growth

9 years

Payout Ratio 5 years average

103 %

Dividend History ABBV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 5.92
Ex Dividend Date 12.10.2023
Forward Annual Dividend Yield 3.86 %
Last Split Factor
Payout Ratio 46.87 %
Last Split Date
Dividend Date 15.11.2023

Stock Valuation ABBV

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 31.428
Forward PE 14.3885
Enterprise Value Revenue 6.0409
Price Sales TTM 4.9887
Enterprise Value EBITDA 13.7968
Price Book MRQ 18.2288

Financials ABBV

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators ABBV

For 52 weeks

128.86 USD 164.38 USD
50 Day MA 147.65 USD
Shares Short Prior Month 11 436 751
200 Day MA 150.02 USD
Short Ratio 3.02
Shares Short 12 454 309
Short Percent 0.71 %